WO1996040073A3 - Composition for sustained release of non-aggregated erythropoietin - Google Patents

Composition for sustained release of non-aggregated erythropoietin Download PDF

Info

Publication number
WO1996040073A3
WO1996040073A3 PCT/US1996/008474 US9608474W WO9640073A3 WO 1996040073 A3 WO1996040073 A3 WO 1996040073A3 US 9608474 W US9608474 W US 9608474W WO 9640073 A3 WO9640073 A3 WO 9640073A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
sustained release
biologically active
epo
polymer
Prior art date
Application number
PCT/US1996/008474
Other languages
French (fr)
Other versions
WO1996040073A2 (en
Inventor
Stephen E Zale
Paul A Burke
Howard Bernstein
Avram Brickner
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Priority to EP96917028A priority Critical patent/EP0871433A2/en
Priority to AU59724/96A priority patent/AU705451B2/en
Priority to NZ309533A priority patent/NZ309533A/en
Priority to JP9501068A priority patent/JPH11506764A/en
Publication of WO1996040073A2 publication Critical patent/WO1996040073A2/en
Publication of WO1996040073A3 publication Critical patent/WO1996040073A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Abstract

A composition, and methods of forming and using said composition, for the sustained release of non-aggregated, biologically active, erythropoietin (EPO). The sustained release composition of this invention comprises a polymeric matrix of a biocompatible polymer and particles of biologically active, aggregation-stabilized EPO, wherein said particles are dispersed within the biocompatible polymer. The method of the invention for producing a composition for the sustained release of biologically active EPO, includes dissolving a biocompatible polymer in a polymer solvent to form a polymer solution, dispersing particles of biologically active, aggregation-stabilized EPO in the polymer solution, and then solidifying the polymer to form a polymeric matrix containing a dispersion of said EPO particles. The method for using a composition of the invention is a method for providing a therapeutically effective blood level of biologically active, non-aggregated erythropoietin in a subject for a sustained period. In this method, a subject is administered an effective dose of the sustained release composition of the present invention.
PCT/US1996/008474 1995-06-07 1996-06-03 Composition for sustained release of non-aggregated erythropoietin WO1996040073A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP96917028A EP0871433A2 (en) 1995-06-07 1996-06-03 Composition for sustained release of non-aggregated erythropoietin
AU59724/96A AU705451B2 (en) 1995-06-07 1996-06-03 Composition for sustained release of non-aggregated erythropoietin
NZ309533A NZ309533A (en) 1995-06-07 1996-06-03 Composition for sustained release of non-aggregated erythropoietin
JP9501068A JPH11506764A (en) 1995-06-07 1996-06-03 Non-aggregated erythropoietin sustained release composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/478,502 1995-06-07
US08/478,502 US5716644A (en) 1992-06-11 1995-06-07 Composition for sustained release of non-aggregated erythropoietin

Publications (2)

Publication Number Publication Date
WO1996040073A2 WO1996040073A2 (en) 1996-12-19
WO1996040073A3 true WO1996040073A3 (en) 1997-01-23

Family

ID=23900212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/008474 WO1996040073A2 (en) 1995-06-07 1996-06-03 Composition for sustained release of non-aggregated erythropoietin

Country Status (11)

Country Link
US (1) US5716644A (en)
EP (1) EP0871433A2 (en)
JP (1) JPH11506764A (en)
CN (1) CN1177612C (en)
AU (1) AU705451B2 (en)
CA (1) CA2223834A1 (en)
CZ (1) CZ390897A3 (en)
MX (1) MX9709699A (en)
NZ (1) NZ309533A (en)
PL (1) PL323736A1 (en)
WO (1) WO1996040073A2 (en)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
AUPO066096A0 (en) * 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
ATE203157T1 (en) * 1996-12-20 2001-08-15 Alza Corp INJECTABLE DEPOSIT GEL PREPARATION AND PRODUCTION METHOD
US6531154B1 (en) 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US20030180368A1 (en) * 1998-03-14 2003-09-25 Cenes Drug Delivery Limited Production of microparticles
ES2347884T3 (en) * 1998-10-23 2010-11-22 Amgen Inc. METHOD AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE ANEMIA.
US7304150B1 (en) * 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US6444223B1 (en) 1999-05-28 2002-09-03 Alkermes Controlled Therapeutics, Inc. Method of producing submicron particles of a labile agent and use thereof
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
CA2408685C (en) * 2000-05-15 2011-02-01 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivate
AU2005225151B2 (en) * 2000-05-15 2008-05-29 F. Hoffmann-La Roche Ag New pharmaceutical composition
US20020076443A1 (en) * 2000-06-19 2002-06-20 Stanley Stein Multiple phase cross-linked compositions and uses thereof
US6998393B2 (en) 2000-06-23 2006-02-14 Biopharm Solutions, Inc. Aquespheres, their preparation and uses thereof
US6719970B1 (en) 2000-07-10 2004-04-13 Alkermes Controlled Therapeutics, Inc. Method of generating cartilage
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
JP2004505761A (en) * 2000-08-15 2004-02-26 ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ Small particles
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US20060269602A1 (en) * 2001-04-13 2006-11-30 Dasch James R Method of modifying the release profile of sustained release compositions
US6558702B2 (en) 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
JP4460892B2 (en) 2001-06-21 2010-05-12 ジェネンテック インコーポレイテッド Sustained release composition
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
PT2656854E (en) 2003-02-04 2015-09-03 Cornell Res Foundation Inc Uses of aromatic-cationic peptide
NZ543410A (en) 2003-05-01 2008-07-31 Cornell Res Foundation Inc Carrier complexes comprising at least one molecule and an aromatic cationic peptide that can cross cell membranes by an energy-independent mechanism and deliver the molecules inside the cell
US7576052B2 (en) 2003-10-17 2009-08-18 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7309500B2 (en) * 2003-12-04 2007-12-18 The Board Of Trustees Of The University Of Illinois Microparticles
RU2392314C2 (en) * 2003-12-30 2010-06-20 Аугустинус БАДЕР Tissue regeneration method
KR101159254B1 (en) 2004-01-23 2012-06-26 코넬 리서치 화운데이션,인크. Methods for reducing oxidative damage
WO2005105886A1 (en) * 2004-04-23 2005-11-10 Amgen Inc. Low molecular weight polylactic acid polymers
US20050260272A1 (en) * 2004-05-05 2005-11-24 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
EP2594259A1 (en) * 2004-08-04 2013-05-22 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060029551A1 (en) * 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
US7748343B2 (en) 2004-11-22 2010-07-06 The Board Of Trustees Of The University Of Illinois Electrohydrodynamic spraying system
US8932633B2 (en) * 2005-08-29 2015-01-13 Biopharm Solutions Inc. Polysaccharide microparticles containing biological agents: their preparation and applications
EP3095454A1 (en) 2005-09-16 2016-11-23 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
CA2709712C (en) 2007-12-20 2016-05-10 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
EP2902036A1 (en) 2008-02-07 2015-08-05 Cornell University Methods for preventing or treating insulin resistance
WO2009108695A2 (en) 2008-02-26 2009-09-03 Cornell University Methods for prevention and treatment of acute renal injury
CN102083969A (en) 2008-05-06 2011-06-01 乔斯林糖尿病中心股份有限公司 Methods and compositions for inducing brown adipogenesis
WO2010085607A1 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Continuous double emulsion process for making microparticles
JP2012521355A (en) * 2009-03-20 2012-09-13 ザ ジェネラル ホスピタル コーポレイション ディー ビー エイ マサチューセッツ ジェネラル ホスピタル Methods for preventing and treating burns and secondary complications
JP2010251707A (en) * 2009-03-27 2010-11-04 Fujitsu Ltd Wiring board, and semiconductor device
JP5909182B2 (en) * 2009-08-12 2016-04-26 コーネル ユニヴァーシティー Methods for preventing or treating metabolic syndrome
EP3708178B1 (en) 2009-08-24 2023-10-04 Stealth BioTherapeutics Inc. Peptide for use in preventing or treating macular degeneration
US20110091518A1 (en) * 2009-09-22 2011-04-21 Danielle Biggs Implant devices having varying bioactive agent loading configurations
EP3120860B1 (en) 2009-10-05 2019-06-26 Cornell University Methods for the prevention or treatment of cardiac fibrosis
EP2910250A1 (en) 2009-12-31 2015-08-26 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP3100739A1 (en) 2009-12-31 2016-12-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
EP3018138A1 (en) 2010-01-25 2016-05-11 Cornell University Aromatic-cationic peptides and uses of same
JP2013521231A (en) 2010-02-26 2013-06-10 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド Mitochondrial targeted antioxidants prevent mechanical ventilation-induced diaphragmatic dysfunction and skeletal muscle atrophy
EP3560508A1 (en) 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
WO2011139992A1 (en) 2010-05-03 2011-11-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN107569675A (en) 2010-07-09 2018-01-12 康德生物医疗技术公司 The method of fluoride-free flux after prevention or treatment ischemia/reperfusion injury
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
CN109705192A (en) 2011-03-24 2019-05-03 康奈尔大学 Aromatic-cationic peptides and application thereof
CN107496899A (en) 2011-09-29 2017-12-22 梅约医学教育与研究基金会 Aromatic-cationic peptide and use their method
CN104114181B (en) 2011-10-17 2017-06-09 康奈尔大学 Aromatic-cationic peptides and application thereof
US20140294796A1 (en) 2011-12-09 2014-10-02 D. Travis Wilson Aromatic-cationic peptides and uses of same
WO2013126597A1 (en) 2012-02-22 2013-08-29 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
EP3513800B1 (en) 2012-02-23 2022-12-07 Cornell University Aromatic-cationic peptide for use in the treatment of antiphospholipid syndrome
CA2880648A1 (en) 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
EP4005582A1 (en) 2012-10-22 2022-06-01 Stealth BioTherapeutics Inc. Treatment of left ventricular remodeling
EP3287172A1 (en) 2012-12-06 2018-02-28 Stealth Peptides International, Inc. Combinations of peptide therapeutics and methods for using same
DK2961378T3 (en) 2013-03-01 2019-11-25 Stealth Biotherapeutics Corp METHODS OF TREATING MITOCHONDRIC DISEASE
EP2961420B1 (en) 2013-03-01 2019-09-11 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
JP2016522196A (en) 2013-05-14 2016-07-28 ステルス バイオセラピューティックス コープ Methods for prevention or treatment of left ventricular remodeling
US9884085B2 (en) 2013-06-26 2018-02-06 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2015009414A1 (en) 2013-06-26 2015-01-22 Stealth Peptides International, Inc. Methods and compositions for regulating srca2a expression levels in myocardial infarction
US10293020B2 (en) 2013-06-27 2019-05-21 Stealth Biotherapeutics Corp. Peptide therapeutics and methods for using same
CA2920020C (en) 2013-08-02 2023-03-14 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
JP2016540762A (en) 2013-12-02 2016-12-28 ステルス バイオセラピューティックス コープ Compositions and methods for the treatment of vitiligo
US20170182117A1 (en) 2014-05-28 2017-06-29 Stealth Biotherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
EP3501532A3 (en) 2014-05-28 2019-07-17 Stealth BioTherapeutics Corp Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
US10627392B2 (en) 2014-06-17 2020-04-21 Stealth Biotherapeutics Corp Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
CN107106637B (en) 2014-08-21 2021-06-25 康德生物医疗技术公司 Methods and compositions for disease prevention and treatment
US10449259B2 (en) 2015-10-02 2019-10-22 Cornell University Enzyme-responsive peptide nanofiber compositions and uses thereof
EP4085920A1 (en) 2016-01-06 2022-11-09 Stealth BioTherapeutics Inc. Methods for the treatment of duchenne muscular dystrophy
EP3458159A4 (en) 2016-05-19 2019-12-18 Stealth BioTherapeutics Corp Compositions and methods for the prevention and treatment of mitochondrial myopathies
CN106273027A (en) * 2016-08-19 2017-01-04 安庆仁生塑胶有限公司 A kind of uniformly plastic particle blender
WO2019032717A1 (en) 2017-08-08 2019-02-14 Memorial Sloan Kettering Cancer Center Use of braf inhibitors for treating cutaneous reactions caused by treatment with a mek inhibitor
RU2705723C1 (en) * 2018-06-26 2019-11-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ЮУГМУ Минздрава России) Rectal suppositories with erythropoietin, having reparative and antioxidant activity
AU2019392670A1 (en) 2018-12-06 2021-07-01 Stealth Biotherapeutics Inc. Methods and compositions for the treatment of Sengers syndrome
WO2020237491A1 (en) 2019-05-28 2020-12-03 Shanghaitech University Composition and methods to treat ectodermal dysplasia 2, clouston type
CN114466656A (en) 2019-07-24 2022-05-10 康德生物医疗有限公司 Peptidomimetic compounds (R) -2-amino-N- ((S) -1- (((S) -5-amino-1- (3-benzyl-1, 2, 4-oxadiazol-5-yl) pentyl) amino) -3- (4-hydroxy-2, 6-xylyl) -1-oxopropan-2-yl) -5-guanidinopentanamide in the treatment of neurodegenerative disorders
CA3156499A1 (en) 2019-10-04 2021-04-08 Stealth Biotherapeutics Inc. Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases
WO2021202986A1 (en) 2020-04-03 2021-10-07 Stealth Biotherapeutics Corp Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia
WO2023069255A1 (en) 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023101963A2 (en) 2021-11-30 2023-06-08 Northwestern University Compositions for inhibiting dipeptide repeat protein-ribosomal rna interaction and uses thereof
WO2023133321A1 (en) 2022-01-10 2023-07-13 Stealth Biotherapeutics Inc. Small molecule peptidomimetic for the treatment of tauopathies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025221A1 (en) * 1992-06-11 1993-12-23 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
WO1996007399A1 (en) * 1994-09-09 1996-03-14 Takeda Chemical Industries, Ltd. Sustained release preparation containing metal salt of a peptide

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3699244A (en) * 1971-08-23 1972-10-17 Singer Co Apparatus to match the color of a monochrome display to average color of an adjacent full color display
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4637905A (en) * 1982-03-04 1987-01-20 Batelle Development Corporation Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
US4906474A (en) * 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
JPS60100516A (en) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
US4891225A (en) * 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
JPS6191131A (en) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd Method and composition for preventing adsorption of pharmaceutical
JPS6197229A (en) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd Stable erythropoietin preparation
US4732889A (en) * 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4981696A (en) * 1986-12-22 1991-01-01 E. I. Du Pont De Nemours And Company Polylactide compositions
JPS6427374A (en) * 1987-03-19 1989-01-30 Eizou Center Kk Large screen display device
DE3729863A1 (en) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh STABILIZED ERYTHROPOIETIN LYOPHILISATES
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
JP2708189B2 (en) * 1988-09-16 1998-02-04 日本放送協会 Wide field of view stereoscopic image display method and apparatus
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
FR2658432B1 (en) * 1990-02-22 1994-07-01 Medgenix Group Sa MICROSPHERES FOR THE CONTROLLED RELEASE OF WATER-SOLUBLE SUBSTANCES AND PREPARATION METHOD.
JPH0463092A (en) * 1990-06-29 1992-02-28 Sanyo Electric Co Ltd Three-dimensional scene display system
CA2099376A1 (en) * 1991-01-03 1992-07-04 Henry E. Auer Stabilization of proteins by cationic biopolymers
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
ATE154240T1 (en) * 1992-03-12 1997-06-15 Alkermes Inc ACTH CONTAINING MICRO SPHERES WITH CONTROLLED RELEASE
PT674506E (en) * 1992-12-02 2001-01-31 Alkermes Inc MICROSPHERES CONTAINING GROWTH HORMONE WITH CONTROLLED LIBERATION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025221A1 (en) * 1992-06-11 1993-12-23 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
WO1996007399A1 (en) * 1994-09-09 1996-03-14 Takeda Chemical Industries, Ltd. Sustained release preparation containing metal salt of a peptide

Also Published As

Publication number Publication date
US5716644A (en) 1998-02-10
EP0871433A2 (en) 1998-10-21
JPH11506764A (en) 1999-06-15
PL323736A1 (en) 1998-04-14
CN1177612C (en) 2004-12-01
AU705451B2 (en) 1999-05-20
CA2223834A1 (en) 1996-12-19
NZ309533A (en) 1999-08-30
AU5972496A (en) 1996-12-30
WO1996040073A2 (en) 1996-12-19
CZ390897A3 (en) 1998-05-13
MX9709699A (en) 1998-07-31
CN1187134A (en) 1998-07-08

Similar Documents

Publication Publication Date Title
WO1996040073A3 (en) Composition for sustained release of non-aggregated erythropoietin
WO1996040072A3 (en) Composition for sustained release of human growth hormone
CA2226166A1 (en) Biocompatible and biodegradable nanoparticles designed for proteinaceous drugs absorption and delivery
HU910707D0 (en) Preparation of regulated emission of active substance and process for manufacturing it
AU658715B2 (en) A process for the preparation of biologically active material-containing polymeric microcapsules
EP0761212A3 (en) Effervescent composition and its production
CA2224074A1 (en) System and method for producing drug-loaded microparticles
NZ508470A (en) Matrices formed of polymer and hydrophobic compounds for use in sustained release drug delivery
AU6798890A (en) Controlled release pharmaceutical preparation and method for producing the same
HUT54861A (en) Process for producing dosage units, dosage units in pressed form and their application
CA2303432A1 (en) Modulation of drug loading in multivesicular liposomes
AU5962496A (en) Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
HUT50050A (en) Pharmaceutical compositions with controlled release of active ingredient and process for producing such compositions
CA2474698A1 (en) Polymer-based compositions for sustained release
DE69735688T2 (en) Controlled release microparticles
WO2000010533A3 (en) Compositions and methods for treating intracellular infections
PL317996A1 (en) Carbamazepinic form of a drug with retarded release of biologically active substance
CA2384301A1 (en) Sustained-release drug formulations for implantation
CA2189254A1 (en) Modulated release from biocompatible polymers
KR0135939B1 (en) Matrix for drug delivery
WO2000076484A1 (en) Pharmaceutical preparation with delayed release of an active substance

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96194611.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 309533

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1997 501068

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2223834

Country of ref document: CA

Ref document number: 2223834

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1997-3908

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1996917028

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1997-3908

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1996917028

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1997-3908

Country of ref document: CZ